Online inquiry

IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14016MR)

This product GTTS-WQ14016MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL33 gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq NM_001199640.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 90865
UniProt ID O95760
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14016MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4127MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BI-505
GTTS-WQ1574MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ12678MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ8859MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ1024MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ12116MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ2560MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ15595MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW